Read how X-Chem successfully searched for compounds capable of inhibiting the novel autotaxin, an enzyme involved in inflammatory signaling and implicated in a wide range of human disease. To find a drug for this high-value target, X-Chem used their proprietary DNA-encoded chemical library platform to screen for autotaxin inhibitors.

In this case study we highlight:

  • Discovery of X-165, a highly potent, selective inhibitor of autotaxin by using DEL technology
  • Characterization of the unique binding modality that differentiates X-165 molecule from any previous autotaxin inhibitor candidate
  • Completion of IND-enabling studies, leading the U.S. FDA to approve X-165 for Phase I clinical trials

Learn more about X-Chem’s drug discovery process of X-165 by reading the full case study.

Get Your Copy Now

Back to Resources